Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (February 2024)

17 slides from Satellos Bioscience's investor presentation, February 2024

  1. Slide 1: Rebuilding muscle from within

    Slide 1: Rebuilding muscle from within

    Rebuilding muscle from within

  2. Slide 2: Legal Disclaimers

    Slide 2: Legal Disclaimers

    Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performa

  3. Slide 3: Corporate Mission and Highlights

    Slide 3: Corporate Mission and Highlights

    Corporate Mission and Highlights We challenge conventions, break scientific ground, and urgently advance drug development, because there’s no time to waste. Our mission is to develop a new class of drugs that treat degenerative muscle conditions by resetting muscle repair and regeneration, thereby r

  4. Slide 4: Experts in muscle stem cell biology, drug development experts, and industry veterans

    Slide 4: Experts in muscle stem cell biology, drug development experts, and industry veterans

    Experts in muscle stem cell biology, drug development experts, and industry veterans Frank Gleeson, MBA Michael Rudnicki, Philip Lambert, PhD Liz Williams, CPA, CA Michael Cross, PhD, MBA Courtney Wells Co-Founder & CEO PhD, OC,FRS, FRSC Chief Scientific Officer Chief FinancialOfficer Chief Business

  5. Slide 5: Satellos – attractive entrance point

    Slide 5: Satellos – attractive entrance point

    Representative Comparators1 Satellos – attractive Market Caps at entrance point Feb. 15, 2024 1 Clinical Stage Phase 1 Phase 2 - 200,000 200 400,000 400 600,000 600 800,000 800 1,000,000 1,000 1,200,000 1,200 1,400,000 1,400 Phase 1/2 Phase 3 Market Capitalization (USD$million) 1. Representative com

  6. Slide 6: Duchenne muscular dystrophy: the patient journey

    Slide 6: Duchenne muscular dystrophy: the patient journey

    Duchenne muscular dystrophy: the patient journey  1:5,000 male babies born annually with Duchenne, a fatal genetic disease.  Mutation(s) in the dystrophin gene leads to a loss or dysfunction of the dystrophin protein.  Satellos discovery: the dystrophin protein is needed in muscle stem cells for

  7. Slide 7: Regeneration is severely compromised in Duchenne

    Slide 7: Regeneration is severely compromised in Duchenne

    Regeneration is severely compromised in Duchenne: due to the absence of dystrophin in muscle stem cells Healthy muscle fibers Duchenne muscle fibers Dystrophin in muscle stem cells Without dystrophin in muscle stem enables regeneration cells, regeneration is blunted Muscle stem cell Regeneration Mus

  8. Slide 8: The role of dystrophin in muscle stem cells can be replaced to restore muscle regeneration

    Slide 8: The role of dystrophin in muscle stem cells can be replaced to restore muscle regeneration

    The role of dystrophin in muscle stem cells can be replaced to restore muscle regeneration  Dystrophin plays a signal transduction role in directing asymmetric stem cell divisions1 symmetric division asymmetric division  Muscle regenerates through asymmetric divisions of dystrophin stem cells into

  9. Slide 9: Satellos lead drug candidate increases progenitor formation and muscle strength in a mouse model of DMD

    Slide 9: Satellos lead drug candidate increases progenitor formation and muscle strength in a mouse model of DMD

    Satellos lead drug candidate increases progenitor formation and muscle strength in a mouse model of DMD Lead drug candidate: SAT-3247 In vitro MyoReGenX Study In vivo 28-day Treatment Study **** p<0.00001 mdx mice n = 10/group SAT-3247 increases progenitor cell formation SAT-3247 increases muscle fo

  10. Slide 10: Duchenne patients walk without any muscle dystrophin

    Slide 10: Duchenne patients walk without any muscle dystrophin

    Duchenne patients walk without any muscle dystrophin The discovery that Duchenne patients were ambulatory, despite having no muscle dystrophin, provides genetic proof of concept that it is possible to have functional muscle in the absence of dystrophin. Also, this report, as well as additional repor

  11. Slide 11: All Duchenne patients have the potential to benefit from Satellos therapeutic approach

    Slide 11: All Duchenne patients have the potential to benefit from Satellos therapeutic approach

    All Duchenne patients have the potential to benefit from Satellos therapeutic approach Therapeutic approaches for Duchenne can be classified into two categories: Dystrophin Dependent Dystrophin Independent Genetic medicines to enhance dystrophin in Activation of a dystrophin-independent pathway to m

  12. Slide 12: MyoReGenX platform powers pipeline expansion

    Slide 12: MyoReGenX platform powers pipeline expansion

    MyoReGenX platform powers pipeline expansion Multiple muscle dystrophies Aging Muscle Injury Cachexia Sarcopenia © 2024 Satellos Biosciences 12

  13. Slide 13: Duchenne program development plan & value catalysts

    Slide 13: Duchenne program development plan & value catalysts

    Duchenne program development plan & value catalysts Lead drug candidate: SAT-3247 IND Enabling Regulatory Regulatory Ph 1b/2a Preclinical submission submission POC Clinical Studies and to begin for POC Trial/s Toxicology Clinical Trial clinical trials Ph 1a Safety SAT-3247 and PK GMP Batch Clinical

  14. Slide 14: Current Financials

    Slide 14: Current Financials

    Current Financials Background Capital Table Common Share 152.5 M Founded 2018 by repeat Warrants 12.3 M entrepreneurs, RTO on TSX.V 2021 Stock Options 13.6 M Strong 2-year cash runway Fully Diluted 178.4 M 50%+ institutional ownership Insiders: ~15% (fully diluted) Cash at 9/30/23 ~CA$44.3M Venture

  15. Slide 15: An enormous market opportunity in which the vast majority of patients go untreated

    Slide 15: An enormous market opportunity in which the vast majority of patients go untreated

    70% of Duchenne patients remain untreated2 7,000-9,500 Duchenne patients in the US1 An enormous market opportunity in which 4 approved drugs for DMD the vast majority of patients go untreated! > $4B DMD market opportunity Multiple Indication expansion opportunities 1 Larkindale, J., Yang, W., Hogan,

  16. Slide 16: REIMAGINE how degenerative muscle diseases are treated

    Slide 16: REIMAGINE how degenerative muscle diseases are treated

    REIMAGINE how degenerative muscle diseases are treated. REGENERATE with novel small molecule medicines. REALIZE the potential to improve lives.

  17. Slide 17: Frank Gleeson, Co-Founder and CEO; Liz Williams CFO

    Slide 17: Frank Gleeson, Co-Founder and CEO; Liz Williams CFO

    Frank Gleeson, Co-Founder and CEO Liz Williams CFO ir@satellos.com | +1.647.660.1780 | www.satellos.com

Source: Internet Archive copy of s203.q4cdn.com

More decks from Satellos Bioscience Inc

All 17 Satellos Bioscience decks